Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
Globe Newswire•06/11/2026•09:00 ET
0
Key Highlights
- ➤Atebimetinib plus anti-PD-1 produced durable complete regressions in 50% of colorectal-cancer mice
- ➤Triple therapy extended lung-cancer mice median survival 1.8-fold to 25 days
- ➤Phase 2 RAS-mutant NSCLC trial expects first-patient dosing by year-end
- ➤Pulsatile MEK inhibition reduced suppressive immune cells while expanding NK cells
Expert Statements
Ben Zeskind, Co-Founder and Chief Executive Officer of Immuneering
“Curing 50% of mice in one tumor model and nearly doubling median overall survival in another are both incredibly exciting. These data add to the body of preclinical evidence that combining a pulsatile inhibitor of MEK with immunotherapy may lead to enhanced activity.”
Ben Zeskind, Co-Founder and Chief Executive Officer of Immuneering
“The ultimate test of this hypothesis will be to show it in patients, and it starts very soon: we expect to dose the first patient by the end of the year in our Phase 2 clinical trial of atebimetinib in combination with anti-PD-1 and chemotherapy in first-line RAS-mutant NSCLC patients.”
- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped -
- Median survival extended by 1.8-fold with atebimetinib plus anti-PD-1 and chemotherapy versus anti-PD-1 plus chemotherapy alone in a RAS-mutant lung cancer model -
Get started
Create a free account to read the full story.